Market Research Logo

Global Ophthalmology Drugs Market to 2023 - Angiogenesis Inhibitors in wAMD Set to Retain High Market Share, While Expansive Pipeline for Glaucoma Leads the Research Landscape

Global Ophthalmology Drugs Market to 2023 - Angiogenesis Inhibitors in wAMD Set to Retain High Market Share, While Expansive Pipeline for Glaucoma Leads the Research Landscape

Summary

Ophthalmology is a broad therapy area that consists of almost 100 disorders associated with the eyes and visual system, including such diseases as glaucoma, age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR) and dry eye syndrome (DES). Many of these disorders are progressive, and if left untreated can lead to severe visual impairment or even blindness.

The ophthalmology market is forecast to grow at a compound annual growth rate (CAGR) of 6.7% till 2023 – with the majority of this growth expected to occur in the final four years of the forecast period. Of the five key indications within the therapy area – glaucoma, AMD, DME, DR and DES – glaucoma and AMD have the most active product pipelines.

Despite the majority of pipeline activity being centered on these five key indications, there is also significant interest in developing products for other indications such as allergic conjunctivitis and retinitis pigmentosa. In 2017, Spark Therapeutics is expected to gain FDA approval for its orphan drug Voretigene Neparvovec, which is currently under development for retinitis pigmentosa and leber congenital amaurosis. If approved, it would not only be the first pharmacological treatment for an inherited retinal disease, but would also be the first gene therapy for any genetic disease to be approved by the FDA.

Six of the eight most commercially successful companies in the ophthalmology therapy area are among the top 20 pharma companies, including Roche, Allergan and Novartis. However, across the forecast period ophthalmology revenue growth for these companies is anticipated to be either negative or lower than the therapy area average. This will be due in part to the fact that ophthalmology products account for only 5% of these companies’ late-stage pipelines.

At the same time, a number of small and specialized ophthalmology companies are expected to enter the market, including Santen and Aerie.

Scope

  • The ophthalmology therapeutics market is forecast to reach $35 billion in 2023. What are the key market segments driving this growth?
  • The pipeline contains over 800 products. What molecule types and molecular targets are in the pipeline? What are the commercial prospects of promising late-stage products?
  • Despite specific drug classes such as angiogenesis inhibitors dominating the commercial landscape, there is a very high proportion of novel drug classes in the pipeline. Which drug classes account for the largest proportion of early-stage development, and how do clinical failure rates, clinical trial size and clinical trial duration differ by indication and molecular target?
  • Although they are dominant in the market, large biotech companies are anticipated to lose market share to specialty ophthalmology companies, which are much more active in the pipeline. Which of the leading companies will have the highest market share by 2023? Which new companies will enter the market?
  • What licensing and co-development deals have occurred within this therapy area since 2006?
Reasons to buy
  • Understand the current clinical and commercial landscape through a comprehensive analysis of innovation in the ophthalmology therapeutics market, in the context of the overall pipeline and current market landscape. The report also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include glaucoma, AMD, DME, DR and DES.
  • Understand the current treatment landscape, with profiles of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
  • Analyze the ophthalmology therapeutics pipeline through a comprehensive review, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at ophthalmology therapeutics clinical trials, to provide an insight into the risk associated with attempting to bring pipeline analgesics to market.
  • Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.
  • Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
  • Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from ophthalmology therapeutic products. In addition, analysis determines the primary factors that will drive market growth for the disease area’s key companies.
  • Assess the licensing and co-development deal landscape for ophthalmology therapies.


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Therapy Area Introduction
      • Glaucoma
      • Age-Related Macular Degeneration
      • Diabetic Retinopathy
      • Diabetic Macular Edema
      • Dry Eye Syndrome
    • Symptoms
      • Table Ophthalmology Disease Therapeutics Market, Symptoms of Glaucoma, AMD, DME, DR and DES
    • Diagnosis
    • Etiology and Pathophysiology
      • Etiology
        • Table Ophthalmology Disease Therapeutics Market, Etiology of Glaucoma, AMD, DME, DR and DES
      • Pathophysiology
    • Co-morbidities and Complications
      • Table Ophthalmology Disease Therapeutics Market, Complications associated with glaucoma, AMD, DR and DES
    • Prognosis
      • Glaucoma
      • Age-Related Macular Degeneration
      • Diabetic Retinopathy and Diabetic Macular Edema
      • Dry Eye Syndrome
    • Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates
      • Table Ophthalmology, Global, Epidemiology of Ophthalmologic Disorders, 2017
      • Glaucoma
        • Table Figure 1: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Glaucoma (millions), 2016–2023
      • Age-Related Macular Degeneration
        • Table Figure 2: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Age-Related Macular Degeneration (millions), 2016–2023
      • Diabetic Macular Edema
        • Table Figure 3: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Diabetic Macular Edema (millions), 2016–2023
      • Diabetic Retinopathy
        • Table Figure 4: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Diabetic Retinopathy (millions), 2016–2023
      • Dry Eye Syndrome
        • Table Figure 5: Ophthalmology, Global, Epidemiology Patterns for Dry Eye Syndrome (millions), 2016–2023
    • Treatment
      • Table Ophthalmology Disease Therapeutics Market, Treatment options available for glaucoma
  • Key Marketed Products
    • Overview
    • Lucentis (ranibizumab)
      • Table Ophthalmology Therapeutics Market, Global, Approved Indications for Lucentis, 2017
      • Table Figure 6: Ophthalmology Therapeutics Market, Global, Annual Revenue for Lucentis ($bn), 2006–2023
    • Eylea (aflibercept)
      • Table Ophthalmology Therapeutics Market, Global, Approved Indications for Eylea, 2017
      • Table Figure 7: Ophthalmology Therapeutics Market, Global, Annual Revenue for Eylea ($bn), 2011–2023
    • Avastin (bevacizumab)
      • Table Ophthalmology Therapeutics Market, Global, Off-label Indications for Avastin, 2016
      • Table Figure 8: Ophthalmology Therapeutics Market, Global, Annual Revenue for Avastin ($bn), 2006–2023
    • Restasis (cyclosporine)
      • Table Ophthalmology Therapeutics Market, Global, Approved Indications for Restasis, 2017
      • Table Figure 9: Ophthalmology Therapeutics Market, Global, Annual Revenue for Restasis ($bn), 2006–2023
    • Alphagan (brimonidine tartrate)
      • Table Ophthalmology Therapeutics Market, Global, Approved Indications for Alphagan, 2017
      • Table Figure 10: Ophthalmology Therapeutics Market, Global, Annual Revenue for Alphagan ($bn), 2006–2023
    • Lumigan (bimatoprost)
      • Table Ophthalmology Therapeutics Market, Global, Approved Indications for Lumigan, 2017
      • Table Figure 11: Ophthalmology Therapeutics Market, Global, Annual Revenue for Lumigan ($bn), 2006–2023
    • Xalatan (latanoprost)
      • Table Ophthalmology Therapeutics Market, Global, Approved Indications for Xalatan, 2017
      • Table Figure 12: Ophthalmology Therapeutics Market, Global, Annual Revenue for Xalatan ($m), 2006–2023
    • Conclusion
  • Pipeline Landscape Assessment
    • Overview
      • Table Figure 13: Ophthalmology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
    • Pipeline Development Landscape
      • Table Figure 14: Ophthalmology Therapeutics Market, Global, Pipeline for Ophthalmology by Stage of Development, Molecule Type and Program Type, 2017
      • Table Figure 15: Ophthalmology Therapeutics Market, Global, Pipeline for Key Ophthalmology Indications by Stage of Development, 2017
    • Molecular Targets in the Pipeline
      • Table Figure 16: Ophthalmology Therapeutics Market, Pipeline by Mechanism of Action (%), 2017
      • Table Figure 17: Ophthalmology Therapeutics Market, Global, Pipeline for Key Ophthalmology Indications by Mechanism of Action, 2017
    • Clinical Trials
      • Failure Rate
        • Table Figure 18: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of
        • Table Figure 19: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2017
        • Table Figure 20: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2017
        • Table Figure 21: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2017
      • Clinical Trial Duration
        • Table Figure 22: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2017
        • Table Figure 23: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2017
        • Table Figure 24: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2017
        • Table Figure 25: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2017
      • Clinical Trial Size
        • Table Figure 26: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2017
        • Table Figure 27: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2017
        • Table Figure 28: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2017
        • Table Figure 29: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2017
      • Aggregate Clinical Program Size
        • Table Figure 30: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006–2017
        • Table Figure 31: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2017
        • Table Figure 32: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2017
        • Table Figure 33: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Mechanism of Action (participants), 2006–2017
      • Assessment of Key Pipeline Products
        • Table Figure 34: Ophthalmology, Global, Revenue Forecast for Lampalizumab ($m), 2018–2023
        • Table Figure 35: Ophthalmology, Global, Revenue Forecast for Fovista ($m), 2017–2023
        • Table Figure 36: Ophthalmology, Global, Revenue Forecast for Brolucizumab ($m), 2017–2023
        • Table Figure 37: Ophthalmology, Global, Revenue Forecast for Voretigene Neparvovec ($m), 2017–2023
        • Table Figure 38: Ophthalmology, Global, Revenue Forecast for Roclatan ($m), 2018–2023
        • Table Figure 39: Ophthalmology, Global, Revenue Forecast for Abicipar Pegol ($m), 2020–2023
      • Conclusion
  • Multi-Scenario Market Forecast to 2023
    • Overall Market Size
      • Table Figure 40: Ophthalmology, Global, Market Size ($bn), 2016–2023
      • Table Opthallmology, Global, Annual Revenue Forecast for Key Products ($bn), 2016-2023
      • Table Figure 41: Ophthalmology, Global, Market Share of Key Products, 2016–2023
    • Generic Penetration
      • Table Figure 42: Ophthalmology, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023
      • Angiogenesis Inhibitors (VEGF/PlGF/PDGF Inhibitors)
        • Table Figure 43: Ophthalmology, Global, Annual Revenue Forecast for Angiogenesis Inhibitors ($bn), 2016–2023
      • Antihistamines (Histamine H1 Receptor)
        • Table Figure 44: Ophthalmology, Global, Annual Revenue Forecast for Antihistamines ($m), 2016-2023
      • Anti-inflammatory Agents (Glucocorticoid Receptor/IL-1 Receptor/Prostaglandin
        • Table Figure 45: Ophthalmology, Global, Annual Revenue Forecast for Anti-inflammatories ($m), 2016–2023
      • IOP Modulators (Prostaglandins, Beta Blockers and the Rho Kinase Signaling
        • Table Figure 46: Ophthalmology, Global, Annual Revenue Forecast for IOP-Lowering Drugs ($bn), 2016–2023
  • Company Analysis and Positioning
    • Table Figure 47: Ophthalmology Therapeutics Market, Global, Cluster by Growth and Market Share, 2016–2023
    • Revenue and Market Share Analysis by Company
      • Table Ophthalmology Therapeutics Market, Global, Forecast Revenues by Company, 2016–2023
      • Table Figure 48: Ophthalmology Therapeutics Market, Global, Forecast Market Share by Company (%),2016–2023
      • Table Figure 49: Ophthalmology, Global, Companies by Compound Annual Growth Rate (%), 2016–2023
      • Table Figure 50: Ophthalmology, Global, Revenues by Product Type, 2014–2022
      • Novartis – Can the Approval of Fovista and Brolucizumab Offset Revenue Lost
        • Table Figure 51: Ophthalmology, Global, Novartis Annual Revenue Forecast ($m), 2016–2023
      • Regeneron – Will Regeneron be Able to Retain its Position in the Ophthalmology
        • Table Figure 52: Ophthalmology, Global, Regeneron Annual Revenue Forecast ($m), 2016–2023
      • Roche – To What Extent Will Pipeline Product Approvals Offset the Patent Expiries
        • Table Figure 53: Ophthalmology, Global, Roche Annual Revenue Forecast ($m), 2016–2023
      • Bayer – Can Bayer Retain its Position in the Ophthalmology Market Given its Small
        • Table Figure 54: Ophthalmology, Global, Bayer Annual Revenue Forecast ($m), 2016–2023
      • Allergan – How Will Declining Revenue from Restasis Affect Allergan's Overall
        • Table Figure 55: Ophthalmology, Global, Allergan Annual Revenue Forecast ($m), 2016–2023
      • Shire – How Will Anticipated New Approvals Perform Across the Forecast Period?
        • Table Figure 56: Ophthalmology, Global, Shire Therapeutics Annual Revenue Forecast ($m), 2016–2023
      • Mallinckrodt – Will its Small Ophthalmology Portfolio and Limited Pipeline be
        • Table Figure 57: Ophthalmology, Global, Mallinckrodt Therapeutics Annual Revenue Forecast ($m), 2016–2023
      • Santen – Will Santen Continue to Rely on Ophthalmology Therapy Area for the
        • Table Figure 58: Ophthalmology, Global, Santen Therapeutics Annual Revenue Forecast ($m), 2016–2023
      • Aerie – Will Aerie be Able to Successfully Enter the Market with Two New
        • Table Figure 59: Ophthalmology, Global, Aerie Annual Revenue Forecast ($m), 2016–2023
    • Company Landscape
      • Table Figure 60: Ophthalmology, Global, Companies by Type, 2017
    • Marketed and Pipeline Portfolio Analysis
      • Table Figure 61: Ophthalmology, Global, High-Activity and Late-Stage Pipeline Developers by Level of Ophthalmology Specialization, 2017
      • Table Figure 62: Ophthalmology, Global, Proportion of Total Company Revenue Attributed to Ophthalmology, 2016–2023
  • Strategic Consolidations
    • Licensing Deals
      • Deals by Region, Year and Value
        • Table Figure 63: Ophthalmology, Global, Licensing Deals by Region, Year and Value 2006–2017
        • Table Figure 64: Ophthalmology Global, Licensing Deals by Indication and Value, 2006–2017
      • Deals by Stage of Development and Value
        • Table Figure 65: Ophthalmology, Global, Licensing Deals by Stage of Development and Value, 2006–2017
      • Deals by Molecule Type, Mechanism of Action and Value
        • Table Figure 66: Ophthalmology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006–2017
      • Table for Licensing Deals Valued Above $100m
        • Table Ophthalmology Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006–2017
    • Co-development Deals
      • Deals by Region, Year and Value
        • Table Figure 67: Ophthalmology, Global, Co-development Deals, 2006–2017
      • Deals by Stage of Development and Value
        • Table Figure 68: Ophthalmology, Global, Co-development Deals by Stage of Development and Value, 2006–2017
      • Deals by Molecule Type, Mechanism of Action and Value
        • Table Figure 69: Ophthalmology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006–2017
      • Table for Co-development Deals Valued Above $100m
        • Table Ophthalmology Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006–2017
  • Appendix
    • References
    • Figures of All Clinical Stage Pipeline Products
      • Table Figure 70: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 1
    • Abbreviations
    • Disease List
    • Methodology
      • Coverage
      • Secondary Research
      • Market Size and Revenue Forecasts
      • Pipeline Analysis
      • Competitive Landscape
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report